coagulation factor VIIa -jncw

ApprovedSmall molecule

AAmerican Thrombosis and Hemostasis Network

coagulation factor VIIa -jncw is one of 39 small molecule programs targeting Hemophilia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemophiliaActive, not recruiting

HemophiliaApproved

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Hemophilia

#DrugCompanyPhaseTrials

Crixivan

Merck & Co.

Approved

1 2

Videx

Bristol-Myers Squibb

Approved

1 3

Hivid

CConrado Roberto Hoffmann Filho

Approved

1 4

Zerit

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 5

Epivir

GGlaxo Dba Glaxosmithkline

Approved

1 6

Cyklokapron

Daklinza

1 8

Recombinant Factor VIII

Bayer

Approved

1 9

Antithrombin Concentrate (ATIIIC)

Sanofi

Approved

3 10

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Hemophilia

NCT04647227

Clinical

Trials by Indication[1]

Hemophilia1 trial

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Recruiting·AAmerican Thrombosis and Hemostasis Network·Phase 4·NCT04647227·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for coagulation factor VIIa -jncw. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — coagulation factor VIIa -jncw compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for coagulation factor VIIa -jncw. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — American Thrombosis and Hemostasis Network company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAmerican Thrombosis and Hemostasis Network

coagulation factor VIIa -jncw

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Hemophilia1 trial

References

Drug Info

Quick Facts

Related News